Globe Life (NYSE:GL) Issues FY 2026 Earnings Guidance

Globe Life (NYSE:GL) updated its FY 2026 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 15.350-15.650 for the period, compared to the consensus estimate of 15.720. Globe Life also updated its FY 2027 guidance to 16.100-17.100 EPS.

Globe Life Stock Performance

GL traded down $10.62 during trading hours on Friday, reaching $157.79. The company’s stock had a trading volume of 321,277 shares, compared to its average volume of 542,148. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.07 and a current ratio of 0.07. The company’s 50-day moving average is $170.48 and its 200-day moving average is $167.25. Globe Life has a 52 week low of $127.85 and a 52 week high of $191.55. The firm has a market cap of $12.13 billion, a PE ratio of 10.48 and a beta of 0.44.

Globe Life (NYSE:GL) last announced its earnings results on Wednesday, October 21st. The company reported $4.84 earnings per share for the quarter, missing analysts’ consensus estimates of $4.90 by ($0.06). The firm had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.56 billion. Globe Life had a return on equity of 19.95% and a net margin of 18.89%. Globe Life’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter last year, the business posted $4.81 EPS. On average, equities analysts forecast that Globe Life will post 15.70 EPS for the current year.

Globe Life Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Monday, October 5th will be issued a dividend of $0.33 per share. The ex-dividend date of this dividend is Monday, October 5th. This represents a $1.32 dividend on an annualized basis and a dividend yield of 0.8%. Globe Life’s payout ratio is 8.76%.

Globe Life declared that its Board of Directors has approved a stock buyback program on Monday, August 10th that allows the company to repurchase $2.50 billion in outstanding shares. This buyback authorization allows the company to reacquire up to 17.7% of its shares through open market purchases. Share buyback programs are often a sign that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on GL shares. JPMorgan Chase & Co. increased their target price on Globe Life from $193.00 to $195.00 and gave the company an “overweight” rating in a research report on Thursday, October 15th. TD Cowen cut their target price on shares of Globe Life from $225.00 to $215.00 and set a “buy” rating on the stock in a research report on Friday. Jefferies Financial Group boosted their target price on shares of Globe Life from $147.00 to $166.00 and gave the stock a “hold” rating in a report on Friday, July 10th. Keefe, Bruyette & Woods decreased their price target on shares of Globe Life from $192.00 to $190.00 and set an “outperform” rating for the company in a research report on Friday, July 24th. Finally, Wells Fargo & Company raised their price target on shares of Globe Life from $190.00 to $191.00 and gave the company an “overweight” rating in a research note on Monday, October 12th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $182.60.

Insider Activity

In other Globe Life news, EVP Michael Majors sold 37,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $178.64, for a total transaction of $6,609,680.00. Following the completion of the transaction, the executive vice president owned 53,518 shares in the company, valued at approximately $9,560,455.52. This trade represents a 40.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Thomas Kalmbach sold 21,000 shares of the business’s stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $180.06, for a total transaction of $3,781,260.00. Following the completion of the transaction, the chief financial officer owned 50,568 shares in the company, valued at $9,105,274.08. This trade represents a 29.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 143,650 shares of company stock worth $25,793,717. 2.11% of the stock is owned by company insiders.

Key Globe Life News

Here are the key news stories impacting Globe Life this week:

• Positive Sentiment: Globe Life reported third-quarter revenue of approximately $1.60 billion, above the $1.56 billion analyst consensus, with revenue up 5.5% year over year. Operating EPS increased to $4.84 from $4.81 a year earlier. Globe Life third-quarter 2026 results
• Positive Sentiment: Management is targeting $850 million to $950 million in parent excess cash flow for 2027, which could support capital returns, debt reduction or other shareholder-friendly actions. The company projects 2027 EPS of $16.10 to $17.10, a range that includes the $16.51 consensus estimate. Globe Life 2027 outlook
• Neutral Sentiment: The company’s 2027 EPS guidance of $16.10 to $17.10 implies continued earnings growth, but the broad range suggests uncertainty around operating performance and future underwriting results.
• Negative Sentiment: Third-quarter operating EPS of $4.84 missed estimates ranging from $4.87 to $4.90. Weaker underwriting income and higher expenses offset gains from increased premiums and investment income. Globe Life Q3 earnings miss
• Negative Sentiment: Globe Life cut its FY 2026 EPS outlook to $15.35-$15.65, below the $15.72 consensus estimate. Reports also cited losses at Evry Health as a factor pressuring the full-year guidance. Evry Health losses and Globe Life guidance
• Negative Sentiment: The quarter included a reported underwriting loss of about $6.4 million, raising investor concerns about claims trends, expense control and the company’s ability to convert premium growth into profits. Globe Life underwriting loss analysis

About Globe Life

Globe Life Inc (NYSE: GL) is an insurance holding company that provides individual life and supplemental health insurance products through a network of wholly owned subsidiaries. Its offerings are designed primarily for middle-income households and include term and whole life insurance, mortgage protection coverage, accident and supplemental health insurance, Medicare supplement policies, and annuities.

The company markets its products through several distribution channels, including exclusive and independent agency networks, direct-to-consumer sales, and workplace or union-affiliated programs.